Migraine trials recruiting in North Carolina

All Migraine trials nationally

Cities in North Carolina

Recruiting trials in North Carolina

• A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine
  NCT07674654 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Charlotte, Greensboro, Raleigh, Shelby
• A Pivotal Clinical Study to Evaluate the MySalvia System for the Treatment of Resistant Migraine
  NCT07719608 · Phase: Not applicable (e.g. observational or device study) · Ages: 22 Years to 84 Years · Sex: All (male and female) · North Carolina: Charlotte
• A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine
  NCT04965675 · Phase: Phase 3 · Ages: 12 Years to 17 Years · Sex: All (male and female) · North Carolina: Charlotte
• A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
  NCT05164172 · Phase: Phase 3 · Ages: 6 Years to 17 Years · Sex: All (male and female) · North Carolina: Charlotte
• A Study of Eptinezumab in Pediatric Participants With Episodic Migraine
  NCT05897320 · Phase: Phase 3 · Ages: 6 Years to 17 Years · Sex: All (male and female) · North Carolina: Charlotte
• A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
  NCT06810505 · Phase: Phase 3 · Ages: 12 Years to 17 Years · Sex: All (male and female) · North Carolina: Greensboro
• A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
  NCT05711394 · Phase: Phase 3 · Ages: 6 Years to 17 Years · Sex: All (male and female) · North Carolina: Greensboro
• A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
  NCT07645924 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · North Carolina: Charlotte, Greensboro, Raleigh, Shelby
• A Study to Learn About the Safety of Taking an Additional Dose of the Medicine Rimegepant in Adults With Migraine
  NCT07609914 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Greensboro
• A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine
  NCT06641466 · Phase: Phase 3 · Ages: 18 Years to 45 Years · Sex: Female · North Carolina: Durham
• A Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of Migraine
  NCT06995729 · Phase: Phase 1 · Ages: 6 Years to 11 Years · Sex: All (male and female) · North Carolina: Statesville, Winston-Salem
• Aimovig Pregnancy Exposure Registry
  NCT06150781 · Phase: Not specified · Ages: 18 Years to 99 Years · Sex: Female · North Carolina: Durham
• BE WELL With Migraine: Brain Education and WELLness With Migraine
  NCT05987592 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Winston-Salem
• BOTOX® vs. XEOMIN® for Chronic Migraine
  NCT05598723 · Phase: Phase 3 · Ages: 18 Years to 89 Years · Sex: All (male and female) · North Carolina: Jacksonville
• Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study
  NCT06972056 · Phase: Phase 4 · Ages: 18 Years to 70 Years · Sex: All (male and female) · North Carolina: Charlotte, Salisbury, Winston-Salem
• Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
  NCT05156398 · Phase: Phase 3 · Ages: 6 Years to 17 Years · Sex: All (male and female) · North Carolina: Fayetteville
• Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
  NCT04743141 · Phase: Phase 3 · Ages: 6 Years to 17 Years · Sex: All (male and female) · North Carolina: Charlotte, Greensboro
• Observational Study to Assess Adverse Events When Adult Female Participants Are Treated With Ubrelvy (Ubrogepant) or Qulipta (Atogepant) During Pregnancy
  NCT05158894 · Phase: Not specified · Ages: 18 Years and older · Sex: Female · North Carolina: Durham
• Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to Rimegepant
  NCT05046613 · Phase: Not specified · Ages: 0 Years and older · Sex: Female · North Carolina: Wilmington
• Randomized Study in Children and Adolescents With Migraine: Acute Treatment
  NCT04649242 · Phase: Phase 3 · Ages: 6 Years to 17 Years · Sex: All (male and female) · North Carolina: Charlotte, Greensboro
• Study of EVO756 in Adults With Migraine
  NCT07616128 · Phase: Phase 2 · Ages: 18 Years to 64 Years · Sex: All (male and female) · North Carolina: Asheville, Raleigh
• Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
  NCT05125302 · Phase: Phase 3 · Ages: 6 Years to 17 Years · Sex: All (male and female) · North Carolina: Charlotte, Hickory